Author: Akazi Shaburishvili
press-releases
Leading research institutions present new data in COVID-19 and glioblastoma research using Lunaphore’s COMET™ technology at the IMMUNOLOGY2023™ Annual Meeting
Date
LAUSANNE, Switzerland – May 11, 2023 – 4:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new data shared in oral presentations within the scientific program and a symposium at IMMUNOLOGY2023™, the Annual Meeting of The American Association of Immunologists (AAI). The research, presented by The University of Birmingham and Northwestern University, showcases the use of spatial biology to investigate COVID-19 and glioblastoma, respectively.
In debut data related to the use of spatial biology in COVID-19 research, Dr. Matthew R. Pugh, FRCPath, of the University of Birmingham, shares a study titled Multi-omic spatial profiling in COVID-19 lung reveals temporal evolution of the disease and novel collagen VI biomarker for outcome, Pugh, M, et al. The abstract selected for a scientific symposium details the team’s research into the tissue response in the lungs of patients with COVID-19, conducting a multi-omic investigation in post-mortem lung tissue from fatal COVID-19 infection using multiplex immunohistochemistry on Lunaphore’s COMET™ as well as bulk Quantseq RNA sequencing, spatial transcriptomic profiling and in situ transcriptomics with RNAscope™. The novel and unpublished results demonstrate the power of post-mortem investigation and spatial profiling in elucidating clinically relevant insights into complex disease phenomena.
Dr. Pugh also presents data in a symposium, The immunopathology of COVID-19 placentitis: A spatial multi-omic approach, Pugh, M. et al., focuses on COVID-19 placentitis, a rare complication of maternal SARS-CoV-2 infection. The presentation outlines multi-omic spatial profiling to characterize placentitis from obstetrically complicated maternal COVID-19 infection, finding that SARS-CoV-2 infected placentas have a distinct transcriptional and immunopathological signature. These results demonstrate a pivotal role for direct placental SARS-CoV-2 infection in driving the unique immunopathology of COVID-19 placentitis.
“These projects offer novel insights in the mechanisms the SARS-CoV-2 virus employs to avoid immune detection and cause disease. I am particularly excited by our findings showing collagen VI is important in mediating disease outcomes in the acute phase of COVID-19”, said Dr. Matthew R. Pugh, MRC Clinical Research Training Fellow at the Institute of Immunology and Immunotherapy, University of Birmingham. “Spatial profiling enabled us to demonstrate that not only is collagen VI upregulated in the lung, but it is deposited in the walls of the lung, contributing to respiratory dysfunction. Such discoveries would not be possible using bulk methodologies.”
Additionally, a poster shared by Northwestern University titled Immune spatial differences between short and long-term surviving glioblastoma patients, Najem, H. et al. highlights how immune surveillance, distribution, interactions, and antigen presentation within the tumor microenvironment (TME) of glioblastoma may influence anti-tumor reactivity and survival. The poster will also be presented in a scientific symposium at the annual meeting.
“Along with our scientific collaborators, we are proud to present new data in expanding disease states which show the growing applications and impact of spatial biology research,” said Ata Tuna Ciftlik, CEO at Lunaphore. The ongoing projects on glioblastoma and COVID-19 are great examples of impactful research from our users. These results underscore the wide range of research areas and broad clinical potential of the COMET™ instrument.”
Scientific program – Block Symposiums details
Immune spatial differences between short and long-term surviving glioblastoma patients
Session: 263 – The Tumor Microenvironment: Mechanisms of Tumor Growth and Metastasis
Date and time: Sunday, May 14 – 4:45 pm EDT
Location: Room 202B
Speaker: Dr. Hinda Najem, Post-doctoral Fellow, Northwestern University
Multi-omic spatial profiling in COVID-19 lung reveals temporal evolution of the disease and novel collagen VI biomarker for outcome
Session: 205 – Immunity to SARS-CoV-2
Date and time: Sunday, May 14 – 11:30 am EDT
Location: Room 201
Speaker: Dr. Matthew R. Pugh, MRC Clinical Research Training Fellow, Institute of Immunology and Immunotherapy, University of Birmingham
Exhibitor Symposium details
The immunopathology of COVID-19 placentitis: A spatial multi-omic approach
Date and time: May 13, 1:45 pm – 2:30 pm EDT
Location: Exhibit Hall D, Room 1
Speakers: Dr. Matthew R. Pugh, MRC Clinical Research Training Fellow, Institute of Immunology and Immunotherapy, University of Birmingham; Dr. Jean Shanks, Pathsoc Intermediate Fellow, Associate Clinical Professor/ Honorary Consultant Histopathologist, Institute of Immunology and Immunotherapy, University of Birmingham
To book a meeting or find out more about Lunaphore’s on-site activities, please visit: https://lunaphore.com/our-events/aai-2023/.
To learn more about Lunaphore, please visit: https://lunaphore.com/.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Lunaphore and Bethyl Laboratories announce partnership to leverage library of primary antibodies on COMET™ platform and expand spatial biology services
Date
LAUSANNE, Switzerland and WALTHAM, Mass. – May 10, 2023 – 6:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Bethyl Laboratories, a Fortis Life Sciences company and provider of high-quality reagents and custom services for discovery, development, and manufacturing, today announced a partnership to promote compatibility and expansion of Bethyl’s library of primary antibodies on Lunaphore’s COMET™ platform.
Bethyl, which has also acquired a COMET™ instrument for use in its facilities, will be able to provide additional services to its customers using the Lunaphore platform. This agreement will enable researchers to leverage Bethyl’s highly qualified antibodies and services with the capabilities of Lunaphore’s COMET™, which is the only fully automated high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies.
Bethyl has manufactured and validated over 35 antibodies for use on the COMET™ and is continuing to add to this portfolio weekly. Bethyl also provides access to Lunaphore’s SPYRE™ Antibody Panels, which can be combined with Bethyl antibodies for panel expansion up to 40-plex.
“We are glad to add Bethyl & Fortis as one of our high-quality partners to help us expand the reach of our spatial biology capabilities. Together, we will be providing researchers with reliable antibodies and assays to support scientific discovery,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “Partnership with scientists has been a pillar of Lunaphore since the beginning, and we are pleased to enter into this agreement with a company that sees a similar value in providing support and quality so that researchers can accelerate their processes with reliable and consistent results.”
“Our proximity to research laboratories will give scientists ready access to the benefits of our primary antibodies combined with the COMET™ platform,” said Dr. Mike Spencer, Sr. Director of Antibody Validation & IHC at Bethyl. “We look forward to expanding our offerings with this partnership to ensure even more customers and researchers can access the capabilities of spatial biology, now paired with the quality antibodies and service they have always enjoyed from Bethyl.”
Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research. To learn more, please visit: https://lunaphore.com/
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About Fortis Life Sciences
Fortis Life Sciences, headquartered in Waltham, MA, partners with life sciences and diagnostics companies to design, develop and manufacture custom integrated reagent solutions. Fortis was founded in 2020 with the mission to offer world-class products & services coupled with best-in-class customer experience. Over the course of two years, Fortis has built a portfolio of high-quality products and brands serving various scientific end markets, including diagnostic, therapeutic, and research. Fortis offers CDMO services for commercial diagnostics and therapeutics (under cGMP & ISO:13485 compliance), custom recombinant & VHH antibody development, nanoparticle synthesis & manufacturing, bulk enzyme & recombinant protein production, and other affinity reagents. To learn more about Fortis Life Sciences, please visit https://www.fortislife.com/.
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Bio-Techne and Lunaphore establish strategic partnership to develop the first fully automated same-slide spatial multiomics solution
Date
Bringing together Bio-Techne’s gold standard RNAscope™ technology with Lunaphore’s multiplex sequential immunofluorescence (seqIFTM) COMETTM system to develop a best-in-class end-to-end multiomics workflow.
MINNEAPOLIS, USA and LAUSANNE, Switzerland, Mass., Apr. 17, 2023 – Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope™ in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases.
“Multiomics spatial imaging has the potential to transform our understanding of disease and accelerate the development of novel therapeutics and next generation diagnostics,” said Kim Kelderman, President of Bio-Techne’s Diagnostics and Genomics Segment. “Together with Lunaphore, we are excited to bring the power of next-generation spatial multiomics to the research community with a fully automated and scalable end-to-end solution delivering robust performance.”
The fully automated multiomics solution will utilize Lunaphore’s revolutionary multiplex sequential immunofluorescence (seqIFTM) solution portfolio including the COMET™ instrument and SPYRE™ Antibody Panels to provide unmatched tissue morphology, scalability, and reproducibility. Ideal for translational and clinical research applications, the COMET™ easily fits within the standard histology workflow to enable hyperplex protein detection at single-cell and subcellular resolution, leveraging existing libraries of non-conjugated primary antibodies.
RNAscope™ HiPlex technology will be included in the automated workflow to enable visualization of RNA biomarkers with industry leading single-molecule sensitivity and specificity. Backed by over 8,000 peer reviewed publications, RNAscope™ has enabled researchers around the world to uncover new breakthroughs across a wide range of different diseases including cancer, neurodegenerative, and immune mediated diseases. With over 45,000 catalog probes available and fast, expert custom probe design available for any gene or species, researchers will be able to easily design and execute novel multiomics panels to achieve their study goals.
“We are thrilled to announce this partnership with Bio-Techne. RNAscope™ has a very well-established place in spatial transcriptomics and the combination with Lunaphore’s fully automated spatial proteomics capabilities will bring an unmatched solution to researchers,” said Ata Tuna Ciftlik, CEO at Lunaphore. “The addition of RNAscope™ HiPlex capability into our recently announced COMET™ product suite will help researchers to truly streamline and automate spatial proteomic, transcriptomic, and multiomics assay workflows with push-button automation, eliminating existing manual upfront steps on all three modalities”.
An initial view of the proof-of-concept data demonstrating the capability of COMET™ to perform an automated same-slide multiomics assay using RNAscope™ will be shared by Ata Tuna Ciftlik this evening at the Lunaphore Dinner Symposium in association with the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Cautionary Note Regarding Forward Looking Statements
This press release contains “forward-looking statements” under applicable securities laws. In some cases, such statements can be identified by words such as: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding our ability to achieve our business strategies, growth, or other future events or conditions. Such statements are based on our current beliefs, expectations, and assumptions about future events or conditions, which are subject to inherent risks and uncertainties, including the risks and uncertainties discussed in the filings we make from time to time with the Securities and Exchange Commission. Actual results may differ materially from those indicated in forward-looking statements, and you should not place undue reliance on them. All statements herein are based only on information currently available to us and speak only as of the date hereof. Except as required by law, we undertake no obligation to update any such statement.
Bio-Techne Investor Contact :
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
[email protected]
Lunaphore Corporate Communications:
Irene Tamayo,
Head of Marketing
[email protected]
Related Articles
press-releases
Lunaphore presents new data developed on its universal end-to-end solution in collaboration with leading research institutes at the AACR Annual Meeting 2023
Date
LAUSANNE, Switzerland – April 14, 2023 – 4:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new data presented in seven posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the COMET™ portfolio’s wide range of research applications and broad clinical potential. These presentations follow the company’s recent announcement of the full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research.
“On the heels of several big milestones for Lunaphore, namely the launch of our comprehensive and future-ready COMET™ product suite, we are very pleased to share a large amount of diverse data at this year’s AACR Annual Meeting,” said Ata Tuna Ciftlik, CEO at Lunaphore. “We’re also thrilled to participate in several collaborative poster presentations, which underscore how we are working with researchers as they use COMET™, rapidly getting up to speed and producing a powerful and large amount of data.”
Two posters focus on Lunaphore’s optimized Immuno-Oncology Core Panel, including:
- A poster titled Validation of a novel multiplex immuno-fluorescence panel for the spatial analysis of the tumor microenvironment demonstrates the robustness of the validated IO Core Panel across multiple COMET™ instruments, tissue banks, and tissue types with highly specific and reproducible results. The data presented in this poster show the robustness and reproducibility of this tool as well as how its reliability compared to traditional methods. This study also shows that marker detection with standard indirect immunofluorescence on the COMET™ instrument allows for rapid expansion and customization of the panel, including additional primary antibodies, which can help answer the needs of individual IO researchers asking unique scientific questions.
- A poster shared in collaboration with the Institute of Neurology (Edinger Institute), University Hospital, Goethe University Frankfurt, Germany, outlines the use of the IO Core Panel in different types of brain metastases (BM), titled Spatial analysis of the immunosuppressive tumor microenvironment in brain cancer applying a novel multiplex immunofluorescence panel. This new study demonstrates a successful application of the IO Core Panel on BM samples combined with additional markers of interest using the flagship COMET™ platform.
Additional presentations underscoring the unmatched capabilities of COMET™ in IO research are shared, as is debut data on HORIZON™, a user-friendly software for image analysis designed and tailored for COMET™ hyperplex images.
- For a poster called Automated multiplex immunofluorescence workflow to interrogate the cellular composition of the tumor microenvironment, researchers utilized Lunaphore’s multiplex sequential immunofluorescence (seqIF™) solution portfolio that combines automated hyperplex execution with image data extraction through HORIZON™ to perform single-cell analysis of the spatial composition of the TME in breast cancer. seqIF™ was performed on COMET™ on breast tissue microarray. The resulting images were further analyzed using HORIZON™ and an in-house developed single-cell analysis pipeline. The study showcases an innovative, automated workflow that eases the adoption of multiplex imaging to explore TME composition at single-cell resolution: slide in, data out.
- Additionally, following the announcement of a co-marketing partnership with Abcam, the two companies present data in a poster titled Automated multiplex immunofluorescence enables single cell analysis of tumor stroma. The study details the creation of a panel of 22 markers for use on COMET™, including the core panel and antibodies from abcam. The findings set the stage for any tumor stroma analysis as COMET™ enables the detailed study of the biology of TME components without requiring lengthy customization processes of the reagent and highlights the heterogeneity of tumor stroma across different tissue types.
Finally, the COMET™ technology that Lunaphore’s end-to-end solution for spatial biology research is built upon was showcased in two posters:
- Spatial dynamics of cytotoxic T Lymphocyte exhaustion in reactive and tumoral tissue focuses on cytotoxic T -cell characterization using COMET™, concluding that the spatial location of inflammatory cells plays a critical role in understanding their functional behavior. Thanks to the COMET™ workflow, it is now possible to analyze this at scale. These technologies will be crucial in investigating the tissue dynamics of possible theranostic markers and development of subsequent clinical trials. This research was conducted in collaboration with the University Hospital Leuven, KU Leuven, Belgium.
- Research conducted in collaboration with Navinci Diagnostics, Sweden, Automation of proximity ligation immunoassay for PD-L1/PD-1 detection in the tumor microenvironment using microfluidic-based system, looks at the use of a proximity ligation assay (PLA) on Lunaphore’s instruments to detect cell-to-cell interactions and protein-to-ligand binding. Researchers evaluated, implemented, and optimized the assays on COMET™ to reduce labor time and cost for the end users. In the next phase, the potential of this assay to be benchmarked as a diagnostic tool in clinical praxis will be thoroughly tested and validated on diagnostic tissue samples from healthy and tumoral tissue types. NSCLC patient cohorts. Researchers believe this approach will enable spatial and functional studies of the interface between the tumor and the immune system and provide necessary information about signaling pathway activation in situ, the latest representing a novel state-of-the-art in tissue diagnostics.
Lunaphore will also hold a spotlight theater with Dr. Hinda J. Najem, Northwestern University, on April 17 at 3 pm EDT, highlighting a universal and comprehensive panel profiling the central nervous system microenvironment facilitated by COMET™.
Furthermore, the company will host a dinner reception during AACR on April 17 at 6:30 pm EDT, delving into the future of spatial biology with invaluable insights from top-notch spatial biology experts, Dr. Denis Schapiro, Heidelberg University Hospital; Dr. Jérôme Galon, INSERM; Dr. Travis Hollmann, Bristol Myers Squibb; Dr. Michael Surace, Director, AstraZeneca, and exclusive details of the novel comprehensive COMET™ product suite.
To book a meeting or learn more about Lunaphore’s presence at the conference, please visit Lunaphore’s website.
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About HORIZON™
HORIZON™ is a tissue analysis software designed to simplify image analysis and evaluation. Tailored to COMET™ hyperplex immunofluorescence images, HORIZON™ extends the COMET™ workflow, providing a seamless integration between both systems, from a hyperplex image to cell phenotyping. HORIZON™ leverages COMET™-generated images and associated protocol information instantaneously. It can support assay development on COMET™, as well as image analysis workflows, by rapidly obtaining precise single-cell data for custom downstream analysis. HORIZON™ can perform cell segmentation in a few clicks thanks to a COMET™-specific, pre-trained algorithm, and the user-friendly and intuitive interface enables hyperplex analysis with no coding experience. With HORIZON™, it is possible to take full control of hyperplex data, visualizing all image channels with full flexibility and accurately finetuning histograms to see the adjustments applied instantly. The pre-release of HORIZON™ is now available for COMET™ users. To learn more about the HORIZON™ software, please visit: https://lunaphore.com/products/horizon/
About SPYRE™ Antibody Panel kits
The four SPYRE™ Antibody Panel kits – IO, Immune, TIL, and T cell Core Panels – lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The assays developed with these kits can be modified or expanded with additional off-the-shelf antibodies from the customer’s own library to build custom panels for specific research needs without complexity. The primary antibody offering also includes Panel Builder, an online application providing exclusive access to a library of more than 70 successfully tested off-the-shelf markers and over 300 protocols. It provides an intuitive and convenient way to combine antibodies with SPYRE™ Antibody Panels to create panel protocols in silico, allowing ready-to-use COMET™ hyperplex protocols to be automatically generated in a few clicks. Orders of SPYRE™ Antibody Panel kits can be placed and will be available for shipment by the summer. To learn more about SPYRE™ Antibody Panels, please visit: https://lunaphore.com/spyre-antibody-panels/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Lunaphore and abcam announce agreement for primary antibody validation for use on COMET™, combining power of trusted antibody provider with superior multiplex capabilities
Date
LAUSANNE, Switzerland and CAMBRIDGE, UK – April 6, 2023 – 5:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.
The agreement will enable researchers to use abcam’s antibodies without conjugation directly on the COMET™ platform, with unparalleled scalability and reproducibility. By using validated primary antibodies together with the capabilities of COMET™, researchers can accelerate assay development processes and achieve reliable results. The partnership also aims to address the reproducibility crisis in life sciences by providing trusted tools for multiplex immunofluorescence analysis.
Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research. Lunaphore’s COMET™ is the only high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. It has a wide range of research applications across multiple disciplines and drug development stages, provides walk-away automation, and allows for the generation of highly robust and reproducible hyperplex data with full tissue preservation that answers the growing needs of translational research.
“This collaboration underscores the importance we place on using antibodies from trusted and proven vendors like abcam. We understand how important it is to the research community to use antibodies that they already know and rely on and be able to directly transfer and use them for multiplexing,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “We are very proud to see how customers can already optimize and run new panels in days. Proposing validated abcam antibodies on COMET will help streamline and scale the researchers’ multiplexing capabilities even more.”
“We’re excited to be partnering with Lunaphore to offer the life science community a library of primary antibodies validated for use with Lunaphore’s automated platform for hyperplex immunofluorescence analysis,” said Courtney Nicholson, Vice President Business Development at abcam. “Spatial biology is truly revolutionizing our understanding of human health and disease, and we are pleased to be working together with Lunaphore to support researchers with the tools they need to further advance this promising new field.”
Lunaphore and abcam will present novel data together in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, highlighting shared research:
Automated multiplex immunofluorescence enables single cell analysis of tumor stroma
Poster #: 4616, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/ .
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About abcam
At abcam, we believe that the scientific community goes further, faster, when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications.
We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
To find out more, visit us at www.abcam.com and corporate.abcam.com.
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Abcam Corporate Communications
Email : [email protected]
Related Articles
press-releases
Lunaphore launches the 2023 SPYRE™ Immuno-Oncology Grant Program, open to all discovery and translational labs in the field of Immuno-Oncology (IO)
Date
LAUSANNE, Switzerland – March 30, 2022 – 4:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the 2023 SPYRE™ Immuno-Oncology Grant Program. It is a unique opportunity for laboratories looking to adopt spatial biology technology to submit a research project application using a spatial hyperplex IO panel. The Program will award a sample testing project on the COMET™ platform, using any desired SPYRE™ Antibody Panel to two winners. The Grant application is open to all discovery and translational labs located in Europe or North America performing IO research and working with human FFPE samples.
The four SPYRE™ Antibody Panel kits, which include the Immuno-Oncology, Immune, TIL, and T cell Core Panels, lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The panels developed with these kits can be expanded with additional antibodies from Lunaphore’s recommended list, containing more than 70 markers and over 300 protocols, as well as with any additional off-the-shelf, non-conjugated primary antibodies from the researcher’s own library to build custom panels with full flexibility to match their specific research needs.
The new SPYRE™ Antibody Panel kits were designed to support researchers in biomarker identification and validation, allowing scientists to kick-start assay development and enable users with verified biomarkers on COMET™. Lunaphore’s aim with the Grant Program is to further lower the barriers to adopting spatial technology in support of the company’s mission of making spatial biology mainstream.
The winners of the Program will be selected based on the project’s scientific impact and the technology fit of its use case with hyperplex spatial analysis on protein targets with SPYRE™. On top of sample testing, winners will also benefit from different prizes, including future discounts and access to protocols and training.
The submission period will be open from March 30 to May 11, 2023, with the winner announcements taking place on May 25, 2023.
To learn more about the SPYRE™ Immuno-Oncology Grant Program and submit your project for consideration, please visit Lunaphore’s website.
To learn more about Lunaphore, please visit: lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About SPYRE™ Antibody Panel kits
The four SPYRE™ Antibody Panel kits – Immuno-Oncology, Immune, TIL, and T cell Core Panel – lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The assays developed with these kits can be modified or expanded with additional off-the-shelf antibodies from the customer’s own library to build custom panels for specific research needs without complexity. The primary antibody offering also includes Panel Builder, an online application providing exclusive access to a library of more than 70 successfully tested off-the-shelf markers and over 300 protocols. It provides an intuitive and convenient way to combine antibodies with SPYRE™ Antibody Panels to create panel protocols in silico, allowing ready-to-use COMET™ hyperplex protocols to be automatically generated in a few clicks. Orders of SPYRE™ Antibody Panel kits can be placed and will be available for shipment by the summer. To learn more about SPYRE™ Antibody Panels, please visit: https://lunaphore.com/spyre-antibody-panels/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Lunaphore expands its COMET™ portfolio to become the first universal, end-to-end spatial biology solution
Date
New products will accelerate the adoption and scalability of groundbreaking translational and clinical research
LAUSANNE, Switzerland – March 28, 2023 – 5:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the launch of a full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research. This milestone marks the launch of the enhanced version of the company’s revolutionary COMET™ platform and its comprehensive product suite, which includes a wide range of tools and applications across all research and drug development stages.
Lunaphore’s multiplex immunofluorescence (mIF) solution portfolio now includes the latest version of the hyperplex, high-throughput, fully automated COMET™ instrument, providing unmatched scalability and reproducibility without the need to conjugate primary antibodies. The new SPYRE™ Antibody Panel kits, Secondary Antibodies, and an online Panel Builder have been added to the existing offering to help kick-start assay development and enable users with verified biomarkers on COMET™.
The product suite is further complemented by HORIZON™, an image analysis software designed and tailored for COMET™ hyperplex images. The software is developed by biologists for biologists to support them in answering fundamental questions about cell profiling and tissue mapping. With Lunaphore’s universal portfolio of precision automation solutions, customers can leverage their existing antibody libraries and decades of know-how on Lunaphore’s platform to scale assays into endless multiplexing possibilities.
“The spatial biology field is at an inflection point, and Lunaphore is at the forefront of this movement with its radically differentiated technological approach. Since the release of the first COMET™ platform a year ago, we so far observed high customer satisfaction and unmatched traction,” said Ata Tuna Ciftlik, CEO at Lunaphore. “We are really excited to launch our comprehensive future-ready solutions. This new COMET™ product suite embeds more than ten years of cutting-edge innovation into powerful tools that accompany our customers, from instant assay creation to streamlined research and analytics. We believe that the COMET ™ product suite is a cornerstone solution that will make spatial biology an everyday tool in laboratories around the globe.”
“A lot of work in our unit is around preclinical and trial work. We immediately recognized COMET™ as the top platform we were after,” said Dr. Andrew Filer, Head of the Birmingham Tissue Analytics Facility at the University of Birmingham. “We wanted a very high plex, fast, and robust instrument. All of the other platforms that were just coming into the market would have one major failure. The reason we liked COMET™ is that it doesn’t have any significant weaknesses. It covers all the bases, which is really important to us.”
Lunaphore’s complete product portfolio will be showcased at the American Association for Cancer Research (AACR) 2023 Annual Meeting through a series of activities and at the Lunaphore booth (#1870). To book a meeting or find out more about Lunaphore’s presence at the conference, please visit Lunaphore’s website.
To learn more about the new products in Lunaphore’s universal, end-to-end solution or start placing requests, please get in touch with the team at: [email protected]
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About HORIZON™
HORIZON™ is a tissue analysis software designed to simplify image analysis and evaluation. Tailored to COMET™ hyperplex immunofluorescence images, HORIZON™ extends the COMET™ workflow, providing a seamless integration between both systems, from a hyperplex image to cell phenotyping. HORIZON™ leverages COMET™-generated images and associated protocol information instantaneously. It can support assay development on COMET™, as well as image analysis workflows, by rapidly obtaining precise single-cell data for custom downstream analysis. HORIZON™ can perform cell segmentation in a few clicks thanks to a COMET™-specific, pre-trained algorithm, and the user-friendly and intuitive interface enables hyperplex analysis with no coding experience. With HORIZON™, it is possible to take full control of hyperplex data, visualizing all image channels with full flexibility and accurately finetuning histograms to see the adjustments applied instantly. The pre-release of HORIZON™ is now available for COMET™ users. To learn more about the HORIZON™ software, please visit: https://lunaphore.com/products/horizon/
About SPYRE™ Antibody Panel kits
The four SPYRE™ Antibody Panel kits – Immuno-Oncology, Immune, TIL, and T cell Core Panel – lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The assays developed with these kits can be modified or expanded with additional off-the-shelf antibodies from the customer’s own library to build custom panels for specific research needs without complexity. The primary antibody offering also includes Panel Builder, an online application providing exclusive access to a library of more than 70 successfully tested off-the-shelf markers and over 300 protocols. It provides an intuitive and convenient way to combine antibodies with SPYRE™ Antibody Panels to create panel protocols in silico, allowing ready-to-use COMET™ hyperplex protocols to be automatically generated in a few clicks. Orders of SPYRE™ Antibody Panel kits can be placed and will be available for shipment by the summer. To learn more about SPYRE™ Antibody Panels, please visit: https://lunaphore.com/spyre-antibody-panels/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Lunaphore raises CHF40M in the first close of Series D funding led by EGS Beteiligungen AG
Date
LAUSANNE, Switzerland – March 23, 2023 – 4:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding. The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB), and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a EUR 10M venture debt facility provided by Norgine Ventures.
The company plans to use the funding to strengthen its growing portfolio offering in spatial biology as well as support commercial execution to address ever-growing demand from customers.
“We are thrilled to have such a highly regarded name like EGSB among our investors. EGSB has an excellent track record of supporting rapidly growing portfolio companies beyond $100M in revenues. In addition, the debt facility from Norgine Ventures will help us to invest in scaling our company even faster,” said Ata Tuna Ciftlik, CEO of Lunaphore. “The funding comes in a meaningful time where we are experiencing excellent traction over the last 12 months since the first launch of our COMET™ product line, and we are very proud to see the world’s best institutions and blue-chip pharma companies among our customers.” COMET™ is currently adopted by the world’s leading research institutions and has been a growth driver for Lunaphore, where COMET™ sales grew more than 350% over 2022. The measured pull-through is best-in-class among existing comparables. “We have proven again that there are endless possibilities provided by turning existing reagent libraries into spatial biology and that true end-to-end precision automation is highly needed in the market.”
EGS Beteiligungen AG is the investment arm of the Ernst Göhner Foundation. EGSB invests with a long-term horizon into established and growth-stage companies based in Switzerland and pursuing global ambitions. Amongst others, EGSB is invested in Sensirion, Spineart, and Beekeeper.
“Cutting edge technology enabling the next frontier in biology & medicine – that is Lunaphore,” summarizes Dominik Sauter, Managing Director of EGS Beteiligungen AG the investment. “Lunaphore is at an inflection point of its trajectory, and we are thrilled to support the leadership team around CEO Ata Tuna Ciftlik in executing on their vision” added Dominik Sauter.
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology with an intuitive approach. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit www.lunaphore.com.
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
press-releases
Lunaphore will reveal new product releases and data at the AACR Annual Meeting 2023
Date
LAUSANNE, Switzerland – March 16, 2023 – 5:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced a series of activities at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19 in Orlando, Florida. These include a dinner symposium, seven data presentations, and a spotlight theatre. The features of the new products will be announced prior to AACR and showcased at the conference.
The novel data and planned activities will outline COMET™’s industry-leading capabilities and highlight its wide range of research applications and broad clinical potential. Lunaphore poster presentations will showcase cutting-edge spatial biology solutions for automated analysis and demonstrate the robustness of new immuno-oncology tools with precise and reproducible results. Collaborative poster presentations will present how researchers are using COMET™ to examine tumors at a single-cell level across different tissue types and spatially analyze and characterize the tumor microenvironment (TME) in multiple cancer types.
The dinner symposium hosted by Lunaphore will feature talks and a roundtable discussion around the future of spatial biology with field experts and the Lunaphore leadership team. The company will also hold a spotlight theater highlighting the flexibility of the automated COMET™ platform to build a universal and comprehensive panel profiling the central nervous system microenvironment.
COMET™ is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible.
Lunaphore poster presentations details
Validation of a novel multiplex immuno-fluorescence panel for the spatial analysis of the tumor microenvironment
Poster #: 5642, Section 43
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
Automated multiplex immunofluorescence workflow to interrogate the cellular composition of the tumor microenvironment
Poster #: 4620, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. Vytautas Navikas, Application Development Scientist, Lunaphore
Collaboration and 3rd party poster presentation details
Spatial dynamics of cytotoxic T Lymphocyte exhaustion in reactive and tumoral tissue
Poster #: 6773, Section 43
Date and time: April 19, 9:00 am – 12:30 pm EST
Speaker: Dr. Maxim De Scheppe, Resident in pathology Ph.D. laboratory for translational breast cancer, KU Leuven
Research conducted by KU Leuven, Belgium
Spatial analysis of the immunosuppressive tumor microenvironment in brain cancer applying a novel multiplex immunofluorescence panel
Poster #: 4619, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. Yvonne Reiss, Group leader, Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany
Research conducted in collaboration with the Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Germany
Immunotopography characterization after neoadjuvant therapy in the pancreatic cancer microenvironment
Poster #: 2254, Section 43
Date and time: April 17, 9:00 am – 12:30 pm EST
Speaker: Dr. Pamela Pulimeno, Scientific Marketing Specialist, Lunaphore
Research conducted in collaboration with the Department of Surgery, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Germany
Automated multiplex immunofluorescence enables single cell analysis of tumor stroma
Poster #: 4616, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
Research conducted in collaboration with Abcam, United Kingdom
Automation of proximity ligation immunoassay for PD-L1/PD-1 detection in the tumor microenvironment using microfluidic-based system
Poster #: 4336, Section 37
Date and time: April 18, 9:00 am – 12:30 pm EST
Speaker: Dr. Agata Zieba Wicher, Chief Scientific Officer, Navinci Diagnostics
Research conducted in collaboration with Navinci Diagnostics, Sweden
Spotlight Theater
Profiling the central nervous system microenvironment using hyperplex immunofluorescence
Date and time: April 17, 3:00 pm – 4:00 pm EST
Location: Theatre D, Orange County Convention Center
Speakers:
- Dr. Hinda J. Najem, Post-doctoral Fellow, Northwestern University
- Doris Loutan, Product Manager, Lunaphore
Affiliated Event | Dinner Symposium
The next decade of spatial biology
Date and time: April 17, 6:00 pm – 11:00 pm EST
Location: Rosen Center; Room: Signature 2
Speakers:
- Prof. Jérôme Galon, Head of the Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers and Director of Research, French National Institute of Health and Medical Research
- Dr. Denis Schapiro, Group Leader, Heidelberg University Hospital
- Dr. Travis Hollmann, Scientific Director, Translational Medicine, Bristol Myers Squibb
- Dr. Ata Tuna Ciftlik, Founder & CEO, Lunaphore
Register here: https://lunaphore.com/our-events/aacr-2023/#form
To book a meeting or find out more about Lunaphore’s on-site activities, please visit: https://lunaphore.com/our-events/aacr-2023/
To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily-integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit: www.lunaphore.com
About COMET™
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]
Related Articles
news
Lunaphore expands flexible spatial biology offering with the launch of secondary antibodies for COMET™
Date
LAUSANNE, Switzerland – March 7, 2023 – 4:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today the launch of its secondary antibodies portfolio. Lunaphore provides the necessary components to unlock the full potential of spatial biology, from instrumentation to secondary antibodies for detection as well as other required reagents.
Lunaphore’s COMET™ is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, facilitating the analysis of 40 different spatial markers per run on a tissue slide. With the introduction of the secondary antibodies portfolio, the company continues to empower researchers to perform successful spatial biology experiments by providing ready-to-use secondary antibodies on the COMET™ platform, minimizing variability.
Lunaphore secondary antibodies have been conjugated to Alexa Fluor™ Plus, comprising key features to yield optimal staining and image quality on COMET™. The Lunaphore pre-adsorbed antibodies ensure low species cross-reactivity. They undergo stringent quality control measures to provide lot-to-lot consistency and integrate into existing experiments with ease to allow high-quality and reproducible results.
“It is critical to listen to our customers: we strive to enhance our product offering and versatile capabilities to ensure that new services integrate seamlessly into existing workflows while providing the highest level of confidence,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “The new secondary antibody kits have been extensively tested to continue delivering the strong stainings and powerful insights that our customers have come to expect. As we expand Lunaphore’s portfolio, we aim to be a vital partner and provider of the best instruments, secondary antibodies, and more so researchers can focus on addressing pressing scientific questions.”
To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
To learn more about the secondary antibodies portfolio, please visit: https://lunaphore.com/secondary-antibodies/
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
About COMET™
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: [email protected]